Supernus Pharmaceuticals received approval from the FDA to market its Oxtellar XR, or oxcarbazepine, extended-release tablets as a monotherapy for patients age 6 and older who have partial-onset seizures. The drug was previously approved as adjunctive treatment for the same indication.
Supernus' partial-onset seizure monotherapy gets FDA nod
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.